NYSE:PFEPharmaceuticals
Is Pfizer’s Late‑Stage Lyme Vaccine Progress Reshaping the Investment Case for PFE?
Earlier this month, Pfizer and Valneva reported that their Phase 3 VALOR trial of the investigational 6‑valent Lyme disease vaccine showed more than 70% efficacy in preventing confirmed Lyme disease cases after the fourth dose, with a favorable safety profile and plans to file with regulators despite one pre-specified analysis missing its statistical criterion.
The results matter because this is the furthest‑advanced Lyme vaccine program in human development, targeting six Borrelia OspA...